Jiangsu Hengrui Pharmaceuticals(600276.SH) received acceptance of the application for the marketing license of SHR4640 tablets.
Hengrui Medicine (600276.SH) announced that the company has received a "Notice of Acceptance" issued by the National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received the "Acceptance Notification" issued by the National Medical Products Administration. The company's application for the market approval of SHR4640 tablets has been accepted by the national drug regulatory authority. The drug is intended for the long-term treatment of primary gout with hyperuricemia.
Related Articles
ESSEX BIO-TECH (01061) repurchased 30,000 shares for HK$61,500 on September 28.
REMEGEN (09995): Tong Shaojing serves as company secretary and authorized representative.
HSBC HOLDINGS (00005) repurchased 871,200 shares for HK$137 million on September 25.
ESSEX BIO-TECH (01061) repurchased 30,000 shares for HK$61,500 on September 28.
REMEGEN (09995): Tong Shaojing serves as company secretary and authorized representative.
HSBC HOLDINGS (00005) repurchased 871,200 shares for HK$137 million on September 25.
